VIATRIS INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
VIATRIS INC. (VTRS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $43.47 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $44.57, a 2.47% decline year-over-year.
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $45.70, a 13.98% decline year-over-year.
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $53.13, a 69.74% increase year-over-year.
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $31.30, a 13.65% increase year-over-year.
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $41.45, a 10.59% decline from fiscal 2024.
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $46.36, a 42.08% increase from fiscal 2023.
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $32.63, a 2.26% increase from fiscal 2022.
- VIATRIS INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $31.91, a 20.92% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $43.47 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $44.57 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $41.45 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $37.98 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $37.04 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $45.70 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $46.36 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $47.43 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $49.75 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $53.13 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $32.63 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $30.53 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $31.42 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $31.30 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $31.91 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $31.37 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $30.69 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $27.54 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $26.39 10-K · filed 2024-02-28 | |||
| 2021-09-30 | $25.24 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $24.77 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $23.47 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $25.74 10-K · filed 2023-02-27 | |||
| 2019-12-31 | $39.40 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $47.86 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |